About the book
There are important biological and behavioral differences between the two genders. These differences strongly affect the epidemiology and pathophysiology of many widespread diseases. The level of sex steroids construes the main physiologic difference between men and women. Estrogen predominance seems to be a health advantage for premenopausal women as compared with men, which may be attributed to their higher estrogen production and an increased transactivation of their estrogen receptors (ERs). In contrast, after menopause with a cessation of ovarian hormone production, women lose their health advantage and they are similarly vulnerable to chronic diseases like men. The paradoxical effects of ovarian hormones on both the promotion and prevention of breast cancer have been debated for over 80 year’s practices of menopausal hormone therapy (MHT). However, the risks and benefits of MHT use may be reconsidered in the light of applied hormone formulas. All toxic complications of synthetic estrogen use and the ambiguous correlations with cancer risk may be explained via understanding the deregulation of ER activation by synthetic estrogens. In contrast, endogenous estrogens are the chief regulators of the genomic machinery in both men and women driving all physiologic functions in healthy cells, whilst inducing apoptotic death in cancer cells.
This book will be a self-contained collection of scholarly papers targeting an audience of practicing researchers, academics, PhD students and other scientists. The contents of the book will be written by multiple authors and edited by experts in the field.